Today’s Short Interest: Capricor Therapeutics Incorporated (NASDAQ:CAPR) Short Interest Increased By 10.31%

November 28, 2016 - By Marie Mckinney   ·   0 Comments

Today's Short Interest: Capricor Therapeutics Incorporated (NASDAQ:CAPR) Short Interest Increased By 10.31%

The stock of Capricor Therapeutics Incorporated (NASDAQ:CAPR) registered an increase of 10.31% in short interest. CAPR’s total short interest was 68,500 shares in November as published by FINRA. Its up 10.31% from 62,100 shares, reported previously. With 56,900 shares average volume, it will take short sellers 1 days to cover their CAPR’s short positions. The short interest to Capricor Therapeutics Incorporated’s float is 1.04%. About 17,600 shares traded hands. Capricor Therapeutics Inc (NASDAQ:CAPR) has declined 23.40% since April 25, 2016 and is downtrending. It has underperformed by 29.41% the S&P500.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology firm focused on the discovery, development and commercialization of therapeutics. The company has a market cap of $63.85 million. The Firm focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. It currently has negative earnings. The Company’s product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction , while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure.

Insitutional Activity: The institutional sentiment increased to 1.33 in Q2 2016. Its up 0.66, from 0.67 in 2016Q1. The ratio improved, as 1 funds sold all Capricor Therapeutics Inc shares owned while 5 reduced positions. 2 funds bought stakes while 2 increased positions. They now own 605,605 shares or 0.05% less from 605,937 shares in 2016Q1.
Moreover, Perceptive Advisors Ltd Llc has 0% invested in Capricor Therapeutics Inc (NASDAQ:CAPR) for 4,000 shares. The New York-based Goldman Sachs Gru Inc has invested 0% in Capricor Therapeutics Inc (NASDAQ:CAPR). Blackrock Fund Advsrs holds 0% or 15,857 shares in its portfolio. Moreover, Globeflex L P has 0% invested in Capricor Therapeutics Inc (NASDAQ:CAPR) for 139 shares. Blackrock Ltd Liability Company reported 1,665 shares or 0% of all its holdings. Moreover, Geode Cap Mgmt Ltd Company has 0% invested in Capricor Therapeutics Inc (NASDAQ:CAPR) for 43,929 shares. Apriem Advsrs holds 0.09% or 70,962 shares in its portfolio. Blackrock Investment Management Limited Liability has invested 0% of its portfolio in Capricor Therapeutics Inc (NASDAQ:CAPR). Moreover, Millennium Mgmt has 0% invested in Capricor Therapeutics Inc (NASDAQ:CAPR) for 18,570 shares. Moreover, Finance Architects has 0% invested in Capricor Therapeutics Inc (NASDAQ:CAPR) for 2,000 shares. Tower Ltd Co (Trc), a New York-based fund reported 770 shares. Brown Advisory accumulated 71,065 shares or 0% of the stock. Moreover, Cordasco Networks has 0.01% invested in Capricor Therapeutics Inc (NASDAQ:CAPR) for 3,100 shares. Morgan Stanley, a New York-based fund reported 41,708 shares. Vanguard Gp holds 0% of its portfolio in Capricor Therapeutics Inc (NASDAQ:CAPR) for 27,975 shares.

Insider Transactions: Since September 21, 2016, the stock had 1 buying transaction, and 0 insider sales for $1.00 million net activity. $1.00M worth of shares were bought by CEDARS SINAI MEDICAL CENTER on Wednesday, September 21.

Capricor Therapeutics Inc (NASDAQ:CAPR) Ratings Coverage

Out of 2 analysts covering Capricor Therapeutics (NASDAQ:CAPR), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Capricor Therapeutics has been the topic of 2 analyst reports since June 15, 2016 according to StockzIntelligence Inc. The rating was reinitiated by H.C. Wainwright with “Buy” on Wednesday, July 6. As per Wednesday, June 15, the company rating was initiated by Roth Capital.

CAPR Company Profile

Capricor Therapeutics, Inc., incorporated on January 26, 2007, is a clinical-stage biotechnology firm focused on the discovery, development and commercialization of therapeutics. The Firm focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. The Firm has over four clinical trials aiming to treat cardiovascular diseases in various progressions of the disease state. The Company’s core technology is based on cardiospheres (CSps), which are multi-cell clusters of cardiac-derived cells. The Company’s lead product candidate, the Cardiosphere-Derived Cells (CDCs), are the single cell monolayer product of the CSps. CDCs are small enough that within acceptable dose limits, they can be injected down a coronary artery without damaging the heart muscle. Both CSps and CDCs are derived from a deceased human donor (allogeneic source) or from heart tissue taken directly from recipient patients themselves (autologous source).

More notable recent Capricor Therapeutics Inc (NASDAQ:CAPR) news were published by: Prnewswire.com which released: “Capricor Therapeutics Reports Third Quarter 2016 Financial Results and …” on November 10, 2016, also Prnewswire.com with their article: “Capricor Therapeutics Announces Closing of Public Offerings Raising …” published on September 21, 2016, Prnewswire.com published: “Capricor Therapeutics Announces Pricing of Offerings of Common Stock” on September 16, 2016. More interesting news about Capricor Therapeutics Inc (NASDAQ:CAPR) were released by: Prnewswire.com and their article: “Capricor Therapeutics Reports Positive 12-Month Data from the DYNAMIC Clinical …” published on June 16, 2016 as well as Prnewswire.com‘s news article titled: “Capricor Therapeutics Appoints Leland J. Gershell, M.D., Ph.D. as Chief …” with publication date: February 23, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marie Mckinney


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>